New antibody shot shows promise for Tough-to-Treat arthritis

NCT ID NCT06590090

Not yet recruiting Disease control Sponsor: XBiotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding a lab-made antibody called natrunix to standard methotrexate treatment helps people with moderate to severe rheumatoid arthritis who haven't improved enough on methotrexate alone. About 108 participants will receive weekly shots of either natrunix or a placebo for 14 weeks, followed by an open-label extension where everyone can get natrunix. The main goal is to see if more people achieve at least a 20% improvement in arthritis symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natrunix (a lab-made antibody similar to a natural human antibody that blocks IL-1a), given as a shot under the skin, plus methotrexate
What this could lead to: If it works, this could offer a new treatment option for people with rheumatoid arthritis who do not respond well to methotrexate alone.
What could go wrong: This is an early Phase 2 trial with only 108 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.